RxDoctor Payments Data
★ My doctorsLook up a doctor →

Pooia Fattahi, MD

Neurological Surgery · Middlebury, CTNPI 1669625174

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $123,136 of the $140,100 with a category attached, or 87.9%. AbbVie accounts for 88.9% of it on its own, with 52 other manufacturers making up the rest. Among neurological surgery clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$140,100in general payments, 2019–2025

Across 797 payments — averaging $175.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$124K
  • Biogen$7K
  • SK Life Science, Inc.$898
  • UCB, Inc.$659
  • Argenx US, Inc.$462
  • Amgen$450
  • plus $6K from 47 others
$89,790in research payments, 2019–2025

Across 21 payments — averaging $4275.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alkermes, Inc.$55K
  • Biogen$33K
  • Novartis$2K

What the payments were for

  • Consulting fees$9891%
  • Speaking & faculty fees$123,13688%
  • Travel & lodging$1,4941%
  • Food & beverage$14,46110%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)413$124,497
Biogen17$7,467
SK Life Science, Inc.38$898
UCB, Inc.20$659
Argenx US, Inc.14$462
Amgen(2 entities)19$450
AstraZeneca21$445
Lilly USA, LLC23$444
Lundbeck LLC17$351
Pfizer16$321
Sanofi17$310
EMD Serono, Inc.17$305
Eisai Inc.11$245
Sunovion Pharmaceuticals Inc.14$240
Acadia Pharmaceuticals Inc11$214
Neurocrine Biosciences, Inc.8$192
CSL Behring8$181
Acorda Therapeutics, Inc9$159
Supernus Pharmaceuticals, Inc.10$143
Genentech USA, Inc.1$125
Penumbra, Inc.1$123
GE HealthCare5$118
Adamas Pharmaceuticals, Inc.7$116
Otsuka America Pharmaceutical, Inc.5$114
Assertio Therapeutics, Inc.5$106
Teva Pharmaceuticals USA, Inc.6$97
Kyowa Kirin, Inc.5$96
Novartis4$89
Bristol Myers Squibb4$89
Scilex Pharmaceuticals Inc.5$88
Biohaven Pharmaceutical Holding Company Ltd.4$86
Livanova USA, Inc.3$72
Collegium Pharmaceutical, Inc.3$70
Amneal Pharmaceuticals LLC4$70
Merz Pharmaceuticals, LLC2$62
Tanabe Pharma America, Inc.3$58
Mallinckrodt Hospital Products Inc.2$48
Alnylam Pharmaceuticals Inc.2$45
Medtronic(2 entities)3$42
Merz North America, Inc.2$41
Biohaven Pharmaceuticals, Inc.2$39
Mallinckrodt Enterprises LLC2$38
Upsher-smith Laboratories LLC2$38
Grifols USA, LLC2$37
Akcea Therapeutics, Inc.2$35
SPR Therapeutics, Inc1$34
Globus Medical1$26
Vertical Pharmaceuticals, LLC1$22
Johnson & Johnson1$21
Nevro Corp.1$19
Avion Pharmaceuticals1$18
Life Molecular Imaging Ltd1$17
Currax Pharmaceuticals LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$140,100 in reported general payments places this provider in the 90th percentile of 94 neurological surgery providers in Connecticut.

See all neurological surgery providers in Connecticut →

Medicare billing

Part B allowed, 2024
$282,919
Medicare patients
463
Services billed
24,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant50$68,334
Memantine Hcl ErMemantine Hcl490$38,428
BotoxOnabotulinumtoxina27$32,974
QuliptaAtogepant23$26,842
Nurtec OdtRimegepant Sulfate20$21,446
Emgality SyringeGalcanezumab-Gnlm12$8,621
Lacosamide38$4,908
Tizanidine Hcl278$3,994
Levetiracetam56$2,376
Quetiapine Fumarate54$1,648
Memantine Hcl37$1,348
Gabapentin40$1,309
Carbamazepine ErCarbamazepine19$1,017
Sumatriptan Succinate35$932
Carbidopa-LevodopaCarbidopa/Levodopa39$883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox, Qulipta$124,497$128,150100 claims
PfizerNurtec Odt$321$21,44620 claims
Upsher-smith Laboratories LLCTopiramate$38$43235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 94 neurological surgery providers in Connecticut.

Other neurological surgery in Middlebury

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →